Get the Stockscreener App
71.24
1.41%
0.99
After Hours:
71.24
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $71.24, with a volume of 4.63M.
It is up +1.41% in the last 24 hours and up +8.65% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$70.25
Open:
$70.42
24h Volume:
4.63M
Relative Volume:
0.80
Market Cap:
$221.10B
Revenue:
$51.21B
Net Income/Loss:
$6.50B
P/E Ratio:
34.17
EPS:
2.085
Net Cash Flow:
$6.76B
1W Performance:
+3.85%
1M Performance:
+8.65%
6M Performance:
-8.55%
1Y Performance:
+6.01%
1-Day Range:
$70.32
$71.44
1-Week Range:
$68.84
$71.44
52-Week Range:
$60.47
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
71.24 | 221.10B | 51.21B | 6.50B | 6.76B | 2.085 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
Deadline Alert: AstraZeneca PLC (AZN) Investors Who Lost - GlobeNewswire
AstraZeneca and GSK put spotlight on pharma as results loom - Proactive Investors UK
Investors in AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN - Stockhouse Publishing
AZN LAWSUIT ALERT: The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - PR Newswire
AstraZeneca (AZN) to Release Quarterly Earnings on Thursday - MarketBeat
2025-01-29 | Shareholders that lost money on AstraZeneca PLC (AZN) should contact Levi & Korsinsky about pending Class ActionAZN | NDAQ:AZN | Press Release - Stockhouse Publishing
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
AstraZeneca's SWOT analysis: pharma giant's stock poised for growth amid challenges - Investing.com
Class Action Filed Against AstraZeneca PLC (AZN)February 21, 2025 Deadline to JoinContact Levi & Korsinsky - Stockhouse Publishing
Levi & Korsinsky Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming DeadlineAZN - Stockhouse Publishing
DEADLINE ALERT for KSPI, CPRI, AZN, RIG: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca - GlobeNewswire
Should AstraZeneca Stock Be in Your Portfolio Pre-Q4 Earnings? - Yahoo Finance
Swedbank AB Purchases 125,600 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Lost Money on AstraZeneca PLC(AZN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Stockhouse Publishing
Iams Wealth Management LLC Increases Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Here's Why Astrazeneca (AZN) is a Strong Value Stock - Yahoo Finance
Orca Wealth Management LLC Invests $4.53 Million in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Russ Mould: what to expect when AstraZeneca and GSK report next week - AJ Bell
AstraZeneca's (AZN) "Buy" Rating Reaffirmed at Berenberg Bank - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AstraZeneca PLC. of Class Action Lawsuit and Upcoming DeadlinesAZN - PR Newswire
Global markets live: Nvidia, Microsoft, Lockheed Martin, AstraZeneca, Airbus… - Marketscreener.com
FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients - Benzinga
AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Shareholders of AstraZeneca PLC Should Contact The Gross Law Firm Before February 21, 2025 to Discuss Your RightsAZN - The Malaysian Reserve
AstraZeneca Scores US Regulatory Approval for Breast Cancer Treatment Enhertu -January 28, 2025 at 06:01 am EST - Marketscreener.com
Blue Trust Inc. Buys 7,686 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca: FDA extends approval of Enhertu -January 28, 2025 at 04:32 am EST - Marketscreener.com
Dynamic Advisor Solutions LLC Cuts Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca, Daiichi’s Drug Wins Wider Use in Breast Cancer Patients - Bloomberg
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC - GlobeNewswire
AstraZeneca, Daiichi Sankyo's Breast Cancer Treatment Wins US Approval -January 27, 2025 at 11:18 pm EST - Marketscreener.com
Chronic Pulmonary Infections Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Teva Pharma, Merck, F. Hoffmann-La Roche, Novartis, GlaxoSmithKline, AstraZeneca - The Globe and Mail
AstraZeneca PLC ADR rises Monday, outperforms market - MarketWatch
AstraZeneca rises Monday, outperforms market - MarketWatch
2025-01-27 | AstraZeneca PLC Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN | NDAQ:AZN | Press Release - Stockhouse Publishing
AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit Filed by The Rosen Law Firm - PR Newswire
2025-01-26 | AstraZeneca PLC Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN | NDAQ:AZN | Press Release - Stockhouse Publishing
AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Asio Capital LLC - MarketBeat
AstraZeneca - Britannica
Goelzer Investment Management Inc. Buys 22,983 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Encompass More Asset Management Makes New $314,000 Investment in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Dakota Wealth Management Sells 6,806 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Class Action Filed Against AstraZeneca PLC (AZN) Seeking Recover - GuruFocus.com
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before - The Bakersfield Californian
AstraZeneca PLC's (LON:AZN) Popularity With Investors Is Clear - Simply Wall St
AstraZeneca Canadian investment to drive R&D growth -January 24, 2025 at 12:01 pm EST - Marketscreener.com
AstraZeneca rises Friday, outperforms market - MarketWatch
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or - GlobeNewswire
Here's Why Astrazeneca (AZN) is a Strong Growth Stock - Yahoo Finance
AstraZeneca Sees Canada As Land Of Opportunity With $570m Investment - News & Insights
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):